BACKGROUND AND PURPOSE: For patients with N1 prostate cancer (PCa) aggressive local therapies can be advocated. We evaluated clinical outcome, gastro-intestinal (GI) and genito-urinary (GU) toxicity after intensity modulated arc radiotherapy (IMAT)+androgen deprivation (AD) for N1 PCa. MATERIAL AND METHODS: Eighty patients with T1-4N1M0 PCa were treated with IMAT and 2-3years of AD. A median dose of 69.3Gy (normalized isoeffective dose at 2Gy per fraction: 80Gy [α/β=3]) was prescribed in 25 fractions to the prostate. The pelvic lymph nodes received a minimal dose of 45Gy. A simultaneous integrated boost to 72Gy and 65Gy was delivered to the intraprostatic lesion and/or pathologically enlarged lymph nodes, respectively. GI and GU toxicity was scored using the RTOG/RILIT and RTOG-SOMA/LENT-CTC toxicity scoring system respectively. Three-year actuarial risk of grade 2 and 3/4 GI-GU toxicity and biochemical and clinical relapse free survival (bRFS and cRFS) were calculated with Kaplan-Meier statistics. RESULTS: Median follow-up was 36months. Three-year actuarial risk for late grade 3 and 2 GI toxicity is 8% and 20%, respectively. Three-year actuarial risk for late grade 3-4 and 2 GU toxicity was 6% and 34%, respectively. Actuarial 3-year bRFS and cRFS was 81% and 89%, respectively. Actuarial 3-year bRFS and cRFS was, respectively 26% and 32% lower for patients with cN1 disease when compared to patients with cN0 disease. CONCLUSION: IMAT for N1 PCa offers good clinical outcome with moderate toxicity. Patients with cN1 disease have poorer outcome.
BACKGROUND AND PURPOSE: For patients with N1 prostate cancer (PCa) aggressive local therapies can be advocated. We evaluated clinical outcome, gastro-intestinal (GI) and genito-urinary (GU) toxicity after intensity modulated arc radiotherapy (IMAT)+androgen deprivation (AD) for N1 PCa. MATERIAL AND METHODS: Eighty patients with T1-4N1M0 PCa were treated with IMAT and 2-3years of AD. A median dose of 69.3Gy (normalized isoeffective dose at 2Gy per fraction: 80Gy [α/β=3]) was prescribed in 25 fractions to the prostate. The pelvic lymph nodes received a minimal dose of 45Gy. A simultaneous integrated boost to 72Gy and 65Gy was delivered to the intraprostatic lesion and/or pathologically enlarged lymph nodes, respectively. GI and GU toxicity was scored using the RTOG/RILIT and RTOG-SOMA/LENT-CTC toxicity scoring system respectively. Three-year actuarial risk of grade 2 and 3/4 GI-GU toxicity and biochemical and clinical relapse free survival (bRFS and cRFS) were calculated with Kaplan-Meier statistics. RESULTS: Median follow-up was 36months. Three-year actuarial risk for late grade 3 and 2 GI toxicity is 8% and 20%, respectively. Three-year actuarial risk for late grade 3-4 and 2 GU toxicity was 6% and 34%, respectively. Actuarial 3-year bRFS and cRFS was 81% and 89%, respectively. Actuarial 3-year bRFS and cRFS was, respectively 26% and 32% lower for patients with cN1 disease when compared to patients with cN0 disease. CONCLUSION:IMAT for N1 PCa offers good clinical outcome with moderate toxicity. Patients with cN1 disease have poorer outcome.
Authors: Janusz Jaszczyński; Zbigniew Kojs; Andrzej Stelmach; Łukasz Wohadło; Elzbieta Łuczyńska; Sylwia Heinze; Janusz Rys; Jerzy Jakubowicz; Piotr Chłosta Journal: Med Sci Monit Date: 2016-07-30
Authors: Valérie Fonteyne; Piet Dirix; Sara Junius; Elke Rammant; Piet Ost; Gert De Meerleer; Martijn Swimberghe; Karel Decaestecker Journal: BMC Cancer Date: 2017-05-02 Impact factor: 4.430
Authors: Florian Sterzing; Clemens Kratochwil; Hannah Fiedler; Sonja Katayama; Gregor Habl; Klaus Kopka; Ali Afshar-Oromieh; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-25 Impact factor: 9.236
Authors: Cai Xu; Mian Xi; Ritsuko Komaki; Peter A Balter; Meilin Huang; Brian P Hobbs; Luhua Wang; Steven H Lin Journal: Adv Radiat Oncol Date: 2017-03-27
Authors: Andrew M McDonald; Samuel J Galgano; Jonathan E McConathy; Eddy S Yang; Michael C Dobelbower; Rojymon Jacob; Soroush Rais-Bahrami; Jeffrey W Nix; Richard A Popple; John B Fiveash Journal: Adv Radiat Oncol Date: 2019-06-19